Differential DiagnosisPatient Lab Decoder
Laboratory-Based Biomarkers • Differential & Genetic Workup

Ruling Out Other Liver Diseases: The Complete Secondary Liver Workup

Plain-language and clinical guide to viral hepatitis, ferritin vs. hemochromatosis, low-titer ANA vs. autoimmune hepatitis, alpha-1 antitrypsin, celiac, Wilson disease, and steatogenic medications.

What This Means for Patients

Every diagnostic flowchart says 'exclude other causes of liver disease,' yet almost nobody hands patients a list of what those blood tests actually are. Confirming MASLD isn't just about proving metabolic risk — it also means making sure a treatable look-alike (like hepatitis C, celiac disease, thyroid slowdown, alpha-1 antitrypsin carrier status, or a medication side effect) isn't quietly driving your numbers.

Equally important, two labs on this workup cause unnecessary panic every single week: mildly high ferritin (seen in up to 40% of MASLD from inflammation alone when transferrin saturation is under 45%) and weakly positive ANA (seen in ~20% of pure MASLD without autoimmune hepatitis). Knowing how hepatologists separate harmless metabolic noise from true genetic or autoimmune disease saves tremendous worry.

False Alarm #1: High Ferritin ≠ Hemochromatosis in Most MASLD

Serum ferritin is elevated in 30%–40% of people with MASLD/MASH simply because ferritin acts as an acute-phase liver inflammation and metabolic stress protein (dysmetabolic hyperferritinemia).1,2 Always check a fasting transferrin saturation (TSAT) alongside ferritin: if TSAT is <45%, elevated ferritin (eg, 300–750 ng/mL) usually reflects metabolic liver stress rather than genetic hemochromatosis.

False Alarm #2: Mild Positive ANA Occurs in ~20% of Pure MASLD

Low-titer antinuclear antibodies (ANA 1:40 to 1:80) or mild anti-smooth muscle antibodies (ASMA) appear in roughly 1 in 5 biopsy-proven MASLD patients who do not have autoimmune hepatitis (AIH).1,3 Clinicians check quantitative serum IgG (typically elevated in true AIH, normal in MASLD) before recommending steroids or a biopsy.

Standard Blood Panel to Rule Out Competing or Coexisting Liver Diseases1,2,4

Condition to Evaluate First-Line Blood Test(s) Confirmatory Step if Abnormal Why It Matters in MASLD
Chronic Hepatitis B & C HBsAg, anti-HBc, anti-HBs; anti-HCV antibody HBV DNA viral load; reflex HCV RNA PCR CDC recommends universal adult screening; coexisting viral hepatitis (“dual etiology”) markedly accelerates cirrhosis risk.1,2
Hereditary Hemochromatosis Serum Ferritin + Fasting Transferrin Saturation (TSAT) If TSAT ≥45%: order HFE genotype (C282Y / H63D) ± MRI iron quantification Untreated C282Y homozygosity causes iron-driven cirrhosis, whereas isolated high ferritin with TSAT <45% improves with metabolic care (phlebotomy does not cure MASH).1
Autoimmune Hepatitis (AIH) ANA, ASMA (anti-actin), quantitative Total Serum IgG Hepatology consult & liver biopsy if IgG is elevated or titers ≥1:160 with ↑ALT/AST Distinguishes true autoimmune interface hepatitis (which requires immunosuppression) from benign MASLD autoantibody positivity.1,3
Alpha-1 Antitrypsin (AAT) Deficiency Serum AAT level + PI phenotype / SERPINA1 genotype (PI*MM, MZ, SZ, ZZ) Pulmonary & hepatology staging; family carrier counseling AAT is an acute-phase protein (inflammation can falsely normalize serum levels). Even carrying one Z allele (PI*MZ) doubles to triples cirrhosis risk when paired with MASLD!1,5
Celiac Disease Tissue transglutaminase IgA (tTG-IgA) + Total Serum IgA Upper endoscopy with duodenal biopsy Explains 3%–5% of chronic unexplained ALT/AST elevations and lean hepatic steatosis; liver enzymes typically normalize on a strict gluten-free diet.4
Wilson Disease Serum Ceruloplasmin (especially if age <40 y or unexplained MASH) 24-hour urinary copper, slit-lamp Kayser-Fleischer ring exam, ATP7B testing Copper accumulation closely mimics fatty liver and MASH on pathology in children, teens, and young adults.1
Cholestatic Liver Disease (PBC / PSC) AMA (anti-mitochondrial antibody) when ALP or GGT is disproportionately elevated MRCP biliary imaging (for PSC) or PBC staging Identifies autoimmune bile-duct injury coexisting with metabolic steatosis.1
Endocrine, Genetic & Medication Drivers TSH (thyroid), PCOS androgen/ovulatory panel, LAL-D enzyme test (in lean youth with ↑LDL / ↓HDL), medication review Treat hypothyroidism/PCOS; review drug alternatives with prescriber Steatogenic drugs that induce or worsen steatohepatitis: amiodarone, methotrexate, tamoxifen, systemic corticosteroids, valproate, and 5-FU/irinotecan.1,2,4